February 16, 2024International Journal of CardiologyOpen Access

Transcatheter bicaval valve system for the treatment of severe isolated tricuspid regurgitation. Features from a single-Centre experience

View Full Paper

Ask AI

Bookmark

Tricuspid regurgitation grade improved significantly alongside reduced right ventricular size, and patients in NYHA class I reached 45% following transcatheter bicaval valve treatment.
Median NT-proBNP decreased from 2873 to 148 pg/mL at follow-up, and median daily furosemide dosage was reduced from 125 mg to 50 mg among eleven surviving patients.
Single-center experience highlights favorable safety for the TricValve system, indicating transcatheter valve interventions offer viable relief for high-risk surgical candidates.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Single-center study demonstrates clinical and hemodynamic improvements following TricValve implantation in severe tricuspid regurgitation, suggesting a viable transcatheter option.

Cite This Study

Mauro et al. (2024) studied this question.

synapsesocial.com/papers/68e78cf9b6db6435876ff1e1 https://doi.org/10.1016/j.ijcard.2024.131864

View Full Paper

Ask AI

Bookmark

Implication

Single-center study demonstrates clinical and hemodynamic improvements following TricValve implantation in severe tricuspid regurgitation, suggesting a viable transcatheter option.

Transcatheter bicaval valve system for the treatment of severe isolated tricuspid regurgitation. Features from a single-Centre experience

Key Points

Discussion

Implication

Cite This Study

Transcatheter bicaval valve system for the treatment of severe isolated tricuspid regurgitation. Features from a single-Centre experience

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider